What Happened?
Shares of global pharmaceutical company Eli Lilly (NYSE: LLY) fell 6.3% in the afternoon session after investment bank HSBC downgraded the stock to a sell-equivalent "reduce" rating from "hold," citing concerns that its shares were "priced to perfection."
The bank's analyst, Rajesh Kumar, also lowered the price target to $850 from $1,070. The downgrade stemmed from a belief that the total market for obesity drugs might be smaller than many analysts forecasted and that future price competition for blockbuster drugs like Zepbound was likely to be significant. HSBC noted that expectations for Eli Lilly's upcoming oral weight-loss pill were also too high.
The shares closed the day at $930.72, down 5.9% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Eli Lilly? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Eli Lilly’s shares are somewhat volatile and have had 11 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 22 days ago when the stock gained 3.8% on the news that a major competitor, Novo Nordisk, announced that its experimental obesity drug failed to show it was as effective as Lilly's tirzepatide in a head-to-head clinical trial.
The late-stage study showed that Novo Nordisk’s drug, CagriSema, achieved a 23% reduction in body weight over 84 weeks, which underperformed the 25.5% weight loss seen with tirzepatide. The results reinforced investor confidence in Eli Lilly's competitive edge in the rapidly growing weight-loss market. Adding to the positive sentiment, the company's weight-loss drug, Zepbound, also received FDA approval for a new multi-dose KwikPen. This new option provided a full month's worth of four weekly injections in a single device, which enhanced convenience for patients.
Eli Lilly is down 13.9% since the beginning of the year, and at $929.68 per share, it is trading 16.2% below its 52-week high of $1,110 from November 2025. Despite the year-to-date decline, investors who bought $1,000 worth of Eli Lilly’s shares 5 years ago would now be looking at an investment worth $4,979.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
